MedTrace Logo

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

NCT00929669 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-11-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.

Conditions

  • Gonadotroph Adenomas

Interventions

DRUG

pasireotide LAR

pasireotide LAR 80 mg IM once a month

Sponsors & Collaborators

Principal Investigators

  • Peter J. Snyder, MD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00929669 on ClinicalTrials.gov